Drug intelligence / Profile preview

IMW-3001

Development stage: Preclinical
Lead developer: Immunowake
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

IMW-3001 is a preclinical-stage multi-specific cytokine fusion protein developed by Immunowake (also known as Longqi Biotechnology) for the treatment of autoimmune diseases. Developed using the company's proprietary TTCyto (TIL-Targeted-Cytokine) platform, the molecule is designed to selectively deliver and activate interleukin-2 (IL-2) signaling at target sites while minimizing systemic toxicities. IMW-3001 targets IL-2 and an undisclosed target (referred to as Target C) to modulate immune responses, potentially promoting regulatory T cell (Treg) activation to restore immune tolerance in autoimmune conditions.

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on IMW-3001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMW-3001.

Explore the full profile